ERBB2 and breast cancer: A recent phase II clinical trial documented the safety of combined treatment of Dasatinib, plus Trastuzumab and Paclitaxel in HER-2-positive metastatic BC patients with acquired resistance to Trastuzumab (NCT01306942, EudraCT 2010-023304-27) [34].